Literature DB >> 18587637

Presence of left ventricular contractile reserve, evaluated by means of dobutamine stress-echo test, is able to predict response to cardiac resynchronization therapy.

Bernardino Tuccillo1, Carmine Muto, Raffaele Iengo, Maria Accadia, Salvatore Rumolo, Micheleangelo Canciello, Giovanni Carreras, Raimondo Calvanese, Eduardo Celentano, Mario Davinelli, Sergio Valsecchi, Luigi Ascione.   

Abstract

INTRODUCTION: We evaluated whether the dobutamine stress-echo test can select responders to cardiac resynchronization therapy (CRT). Up to 50% of patients do not respond to CRT. Lack of response may be due to a significant amount of scar or fibrotic tissue at myocardial level. METHODS AND
RESULTS: We studied 42 CRT patients. After clinical and echocardiographic evaluation, all patients underwent a dobutamine stress-echo test to assess contractile reserve. Cut-off for the test was an increase of 25% of the left ventricular ejection fraction. Patients were implanted with a CRT-defibrillator and followed up at 6 months. Cut-off for CRT response was a reduction of 15% of left ventricular end-systolic volume. Twenty-five patients responded to CRT; all of them showed presence of contractile reserve. The test showed a sensitivity of 100% and a specificity of 88%.
CONCLUSION: Contractile reserve was a strong predictive factor of response to CRT in the studied population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587637     DOI: 10.1007/s10840-008-9255-9

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  30 in total

1.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

2.  Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony.

Authors:  James A White; Raymond Yee; Xiaping Yuan; Andrew Krahn; Allan Skanes; Michele Parker; George Klein; Maria Drangova
Journal:  J Am Coll Cardiol       Date:  2006-10-31       Impact factor: 24.094

Review 3.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

4.  Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias.

Authors:  I Lozano; M Bocchiardo; M Achtelik; F Gaita; H J Trappe; E Daoud; J Hummel; C Duby; P Yong
Journal:  Pacing Clin Electrophysiol       Date:  2000-11       Impact factor: 1.976

5.  Area of left ventricular regional conduction delay and preserved myocardium predict responses to cardiac resynchronization therapy.

Authors:  Hung-Fat Tse; Kathy Lf Lee; Siu-Hong Wan; Yinghong Yu; Walter Hoersch; Joseph Pastore; Qingsheng Zhu; Bruce Kenknight; Julio Spinelli; Chu-Pak Lau
Journal:  J Cardiovasc Electrophysiol       Date:  2005-07

6.  The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points.

Authors:  J G Cleland; J C Daubert; E Erdmann; N Freemantle; D Gras; L Kappenberger; W Klein; L Tavazzi
Journal:  Eur J Heart Fail       Date:  2001-08       Impact factor: 15.534

Review 7.  The problem of non-response to cardiac resynchronization therapy.

Authors:  David H Birnie; Anthony Sl Tang
Journal:  Curr Opin Cardiol       Date:  2006-01       Impact factor: 2.161

8.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

9.  Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Authors:  Frank F Seghatol; Dipan J Shah; Silvia Diluzio; David Bello; Maryl R Johnson; William G Cotts; Jenny A O'Donohue; Robert O Bonow; Mihai Gheorghiade; Vera H Rigolin
Journal:  Am J Cardiol       Date:  2004-04-01       Impact factor: 2.778

10.  Myocardial perfusion imaging using gated SPECT in heart failure patients undergoing cardiac resynchronization therapy.

Authors:  Roberto Sciagrà; Marzia Giaccardi; Maria Cristina Porciani; Andrea Colella; Antonio Michelucci; Paolo Pieragnoli; Gianfranco Gensini; Alberto Pupi; Luigi Padeletti
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

View more
  3 in total

Review 1.  Current role of echocardiography in cardiac resynchronization therapy.

Authors:  Donato Mele; Matteo Bertini; Michele Malagù; Marianna Nardozza; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

2.  Acute contractile recovery extent during biventricular pacing is not associated with follow-up in patients undergoing resynchronization.

Authors:  Federica DeVecchi; Emanuela Facchini; Anna Degiovanni; Chiara Sartori; Chiara Cavallino; Matteo Santagostino; Virginia Di Ruocco; Andrea Magnani; Eraldo Occhetta; Paolo Nicola Marino
Journal:  Int J Cardiol Heart Vasc       Date:  2016-04-01

3.  Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy.

Authors:  Julien Magne; Michelle Dubois; Jean Champagne; Jean G Dumesnil; Philippe Pibarot; François Philippon; Gilles O'Hara; Mario Sénéchal
Journal:  Cardiovasc Ultrasound       Date:  2009-08-20       Impact factor: 2.062

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.